Jade Biosciences Inc expected to post a loss of 43 cents a share - Earnings Preview
08/08/2025 13:46
Jade Biosciences Inc JBIO.OQ JBIO.O is expected to show no change in quarterly revenue when it reports results on August 11 (estimated) for the period ending June 30 2025 LSEG's mean analyst estimate for Jade Biosciences Inc is for a loss of 43 cents per share. The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for Jade Biosciences Inc is $16.50, about 55.6% above its last closing price of $7.32 Previous quarterly performance (using preferred earnings measure in US dollars).
| QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
| Mar. 31 2025 | -4.55 | -8.40 | -3.15 | Beat | 62.5 |
| Dec. 31 2025 | -6.65 | -8.75 | -6.65 | Beat | 24 |
| Sep. 30 2024 | -21.70 | -20.39 | -19.60 | Beat | 3.9 |
| Jun. 30 2024 | -28.65 | -28.77 | -30.10 | Missed | -4.6 |
| Mar. 31 2024 | -26.83 | -26.77 | -29.05 | Missed | -8.5 |
| Dec. 31 2023 | -24.80 | -24.77 | -25.90 | Missed | -4.6 |
| Sep. 30 2023 | -24.42 | -24.21 | -24.85 | Missed | -2.7 |
| Jun. 30 2023 | -24.63 | -24.36 | -26.60 | Missed | -9.2 |
Recent news on Jade Biosciences
See all newsBrief: Jade Biosciences Announces Preclinical Data Characterizing Jade301, A Potentially Best-In-Class, Half-Life-Extended Anti-Ifn-Β Monoclonal Antibody In Development For Dermatomyositis, At Eadv 2026
U.S. RESEARCH ROUNDUP-Cardinal Health, Lumentum Holdings, Public Storage
Jade Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary
Jade Biosciences Q2 net loss widens as costs rise
Brief: Jade Biosciences, Inc Q2 Cash & Investments USD 461.2 Million